← back to ranking

DXCM · DexCom, Inc.

Medical - Devices · mkt cap $28.3B · calls: Q1 FY2026 vs Q4 FY2025
42.0 conviction · conf-adj 42

conf –

enthusiasm:21.0 · trend:0 · quantifies:0 · impact:0 · under_radar:5 · credibility:5 · business_impact:8 · disruption:0 · commitment:0 · confirmation:3

Enthusiasm latest 7 / prev 7 (flat)

DexCom's AI thesis is product-led: personalized Stelo insights, AI meal analysis, Smart Basal dosing support, and analytics-driven sales targeting are meant to improve engagement, utilization, retention, outcomes, and share. Management also says AI is helping efficiency, but it does not quantify the contribution to revenue, margins, cost savings, headcount, or productivity. The story is credible as a recurring part of the product roadmap, but still mostly qualitative and forward-looking.

PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

60/100 track record   delivers  6 calls reviewed

DexCom's AI commitments are milestone-based product launches (Smart Basal titration, AI food logging) rather than hard revenue/cost-savings targets, and the judgeable ones were generally delivered on or near the stated timeframe. Track record looks reliable but the sample is thin and several recent promises are still too-early to grade.

DexCom Smart Basal (ML-driven personalized insulin-titration module) to begin early-access launch 'this month' (Jan 2026) — promised Q4 FY2025
delivered By Q1 FY2026 they confirmed Smart Basal was 'expanding access within our pilot KOLs,' so the early-access launch began on the committed timeframe
Smart Basal titration algorithm 'currently under review with the FDA and for CE Mark,' to become available once cleared — promised Q3 FY2025
partial Progressed to early-access/pilot-KOL launch by Q4 FY2025–Q1 FY2026, tracking toward availability as stated
AI Smart Food Logging to be enhanced with a comprehensive nutrition database/macronutrient breakdown, launching 'shortly' — promised Q4 FY2025
too-early Q1 FY2026 said macronutrient info and AI food-logging upgrades were coming 'in the coming weeks' as part of the Stelo redesign — in progress, not yet confirmed shipped
Complete Stelo app redesign with 'more AI-driven personalized insights' to roll out to all customers 'in the coming weeks' — promised Q1 FY2026
too-early Timeframe had not elapsed by end of the transcript set; cannot yet judge
Stelo's proprietary generative-AI feature to expand functionality 'over time' as a key source of personalized content — promised Q4 FY2024
partial They did keep adding AI features (Smart Food Logging, planned AI insights), but the original claim carried no hard number/date
PRICED-IN (REFINED)
MEDIUM

Est. revisions falling  ·  Fwd P/E 35.7  ·  EV/Sales 5.9x

AI claim maps to UNITED STATES, Non-US

Estimate signals are falling: ratings are not migrating higher and price targets have moved down from lastYearAvg 82.75 to lastQuarterAvg 78.25 to lastMonthAvg 73, even though consensus still bakes in solid FY revenue and EPS growth. Valuation is rich at 35.7x forward EPS and about 5.9x EV/Sales, which means some upside is already capitalized despite weaker revision momentum. With no product segmentation available, an AI efficiency or revenue claim would most plausibly map across the reported geographic segments UNITED STATES and Non-US. The verdict is medium because rich valuation points to priced-in upside, but falling revisions prevent a high priced-in call.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
6Q4 FY20244Q1 FY20258Q2 FY20258Q3 FY20258Q4 FY20258Q1 FY2026

AI enthusiasm across 6 calls — trend ↗ rising

AI moved from early Stelo personalization to concrete food logging, dosing, support, and customer-experience modules tied to engagement and outcomes.

RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY

7/10 qualitative impact   material  medium-term · soft evidence

Where AI matters: CGM product experience, dosing support, engagement, sales targeting

DexCom is embedding AI into core CGM-adjacent software: Stelo personalized insights and meal analysis, Smart Basal dosing support, and data-driven prescriber targeting. That can improve engagement, utilization, retention, outcomes, and share, but evidence is still mostly milestone/product-roadmap qualitative with no quantified revenue or margin contribution.

Caveats: No quantified AI revenue, EPS, cost-savings, or productivity impact disclosed; Smart Basal remains in pilot/early access and clinical workflow fit is unproven at scale; Regulatory and liability constraints may slow AI dosing-support rollout; AI insights may improve retention but not materially change sensor adoption or pricing

AI DISRUPTION / CANNIBALIZATION RISK  tailwind · 1/10

AI does not plausibly commoditize DexCom's core model, which rests on regulated sensors, clinical trust, reimbursement, data scale, distribution, and device reliability. The bigger risk is AI-enabled competitors improving decision support around CGM data, but that is competitive pressure rather than AI automating away DexCom's product.

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $385M · beta 1.398 · px $73.45

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 5/10 measured.
INSIDERS selling 6 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 147 new / 115 closed positions; 520 increased / 326 reduced; institutional ownership -0.70pp; +18 net 13F holders
MGMT LANGUAGE 5/10 measured AI discussion is limited; Stello rollout sounds firm, but business impact language is mostly qualified and aspirational.
commit “In the coming weeks, we will introduce this new experience to all customers”
commit “which will offer a more consumer-friendly feel, more AI-driven personalized insights”
hedge “This personalized dosing module has the potential to reinvent basal insulin management”
VERBATIM AI QUOTES
“In the coming weeks, we will introduce this new experience to all customers, which will offer a more consumer-friendly feel, more AI-driven personalized insights, and additional food logging capabilities including detailed macronutrient information.”
— Jacob Steven Leach, Q1 FY2026
“For our G Series products, we are currently expanding access within our pilot KOLs for our DexCom, Inc. Smart Basal feature. This personalized dosing module has the potential to reinvent basal insulin management by driving more accurate insulin titration, accelerating the time needed to reach optimal dose, and delivering improved outcomes for customers and physicians.”
— Jacob Steven Leach, Q1 FY2026
“Over time, we started adding features to the current version of Stello, particularly focused around capture of nutrition—meal logging—using AI to analyze those meals.”
— Jacob Steven Leach, Q1 FY2026
“The new Stello app we are launching very shortly is a complete redesign of the user interface. It has a more technology-forward aesthetic and provides insights that add context to glucose excursions, glucose variability, and nutrition.”
— Jacob Steven Leach, Q1 FY2026
“We wanted to make insights much more personalized and take advantage of integrated data from activity trackers—Oura Ring, sleep scores, and more—bringing more personalized context and analysis.”
— Jacob Steven Leach, Q1 FY2026
“We did good work managing expenses and leaning into things like AI to be more efficient, but we are not pulling back on R&D.”
— Jereme M. Sylvain, Q1 FY2026
“On the salesforce, we are using advanced tools to analyze data and target—find these patients, find their prescribers.”
— Jacob Steven Leach, Q1 FY2026
“We also have additional offerings planned as we further integrate AI into this customer experience in the near future.”
— Jacob Leach, Q4 FY2025
“We believe this personalized dosing module can lead to more accurate basal insulin titration, accelerate the time to reach optimal dose, significantly simplify workflows for the prescriber and most importantly, improve outcomes for those using our products.”
— Jacob Leach, Q4 FY2025
“For Stelo, we recently announced a comprehensive nutrition database that will be launched shortly in our smart food logging feature.”
— Jacob Leach, Q4 FY2025
“Following this update, Stelo can provide a detailed breakdown of macronutrient information for each meal, giving customers a better understanding of how food choices impact their glucose.”
— Jacob Leach, Q4 FY2025
“And so as we make the software updates, we start adding more AI insights to the technology, the idea is, can we drive utilization even higher?”
— Jacob Leach, Q4 FY2025
“In all of those aspects, if you think about that whole journey, there's many things that we can continue to enhance digitally through software, whether it's for the physician or for the patient themselves to help them onboard faster to really -- our goal is to remove friction, to remove any kind of speedbumps so that they get the experience that is the highest caliber.”
— Jacob Leach, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Issie Kirby): I wanted to ask about Stello and how that is tracking. What prompted the redesign? With the international launch, how broad do you expect to go? Is this a product that you could push into markets where you are not currently present?
A: We see Stello as a fantastic opportunity to reach more patients, and it is tracking well to our estimates. As we have been out there for over a year, we have learned quite a bit. One of the main things we are hearing from users is they want more context around real-time glucose data. Over time, we started adding features to the current version of Stello, particularly focused around capture of nutrition—meal logging—using AI to analyze those meals.
Q (Q1 FY2026, Jayson Tyler Bedford): The Smart Basal launch, I think it was early access in 1Q. When do you expand this launch?
A: We are still in a pilot launch. The idea is making sure the system as designed fits into workflow because it is designed to be a very broad-use product across many clinical environments—large diabetes clinics and small primary care offices.
Q (Q1 FY2026, Chris Pasquale): I am looking in particular at R&D being flat in dollar terms as an outlier. Any color there would be great.
A: We did good work managing expenses and leaning into things like AI to be more efficient, but we are not pulling back on R&D.
Q (Q1 FY2026, Daniel Markowitz): Is there anything you are doing to the organization or the salesforce in order to prepare for this market unlock—maybe more focus on PCPs versus endos? Also, how should we think about the operating impact related to increasing contribution from the type 2 non-insulin market going forward?
A: On the salesforce, we are using advanced tools to analyze data and target—find these patients, find their prescribers.
Q (Q4 FY2025, Danielle Antalffy): I'm just curious, as you guys are sort of thinking about not only 2026 but beyond, and obviously don't want to front run the Analyst Day, but even qualitatively, how to think about utilization based on what you know today?
A: And so as we make the software updates, we start adding more AI insights to the technology, the idea is, can we drive utilization even higher?
Q (Q4 FY2025, Jayson Bedford): And do you view Smart Basal as a tool to kind of reintroduce G7 to this population and drive better growth?
A: To your point, we do feel like Smart Basal is a great opportunity for us to meet the needs of the patients.
Q (Q4 FY2025, Brandon Vazquez): Maybe just spend a minute, talk to us a little bit about what is left in the pipeline on the software side. Like what else can you do here? What else can you leverage the software side for?
A: No, we are nowhere near done. There's so much more we can do on both, as you mentioned, the hardware, but also on the software.